公开(公告)号：US20240293536A1

公开(公告)日：2024-09-05

申请号：US18394532

申请日：2023-12-22

申请人： National Pingtung University Of Science And Technology

发明人： Hso-Chi Chaung ,  Wen-Bin Chung ,  Yen-Li Huang ,  Chi-Chih Chen ,  Yu-Chieh Chen

IPC分类号： A61K39/295 ,  A61K39/00 ,  A61K39/12 ,  A61P37/04

CPC分类号： A61K39/295 ,  A61K39/12 ,  A61P37/04 ,  A61K2039/552 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/70

摘要： The present invention relates to a porcine bivalent subunit vaccine composition in a single dose. The porcine bivalent subunit vaccine composition includes porcine bivalent antigen, CpG adjuvant and a dual phase adjuvant. The porcine bivalent antigen consists of a classical swine fever virus (CSFV)-E2 recombinant protein and a porcine circovirus type 2 (PCV2)-ORF2 recombinant protein, both of which are produced by a mammalian cell expression system. The porcine bivalent subunit vaccine composition in a single dose can confer effectively immune protection against CSFV and PCV2 via a single vaccination without boost vaccination.

公开(公告)号：US20240269266A1

公开(公告)日：2024-08-15

申请号：US18601925

申请日：2024-03-11

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Lbachir BenMohamed

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61K39/295 ,  C12N15/86

CPC分类号： A61K39/215 ,  A61K39/295 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/70 ,  C12N2750/14143 ,  C12N2770/20034

摘要： Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

公开(公告)号：US20240261398A1

公开(公告)日：2024-08-08

申请号：US18634012

申请日：2024-04-12

申请人： The University of Tokyo

发明人： Yoshihiro KAWAOKA ,  Huapeng FENG ,  Tokiko WATANABE ,  Makoto YAMASHITA

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/295 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/145 ,  A61K39/295 ,  C12N7/00 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55577 ,  A61K2039/55583 ,  A61K2039/70 ,  C12N2760/14134 ,  C12N2760/14171 ,  C12N2760/16034 ,  C12N2760/16071

摘要： The present invention is intended to provide an adjuvant having high safety to living bodies and an action to sufficiently reinforce immune function, and a vaccine comprising the adjuvant. Specifically, the present invention relates to 34 novel adjuvant candidate compounds, which have been identified by screening 145 food additives and 51 injection additives, using, as indicators, an increase in the antibody titer against influenza virus and a protective effect against infection with influenza virus, and then selecting those having the function of increasing the antiviral antibody titer in blood and the protective effect against viral infection. In addition, the present invention also relates to a vaccine comprising these adjuvant candidate compounds.

公开(公告)号：US20240123062A1

公开(公告)日：2024-04-18

申请号：US18471955

申请日：2023-09-21

申请人： University of Massachusetts

发明人： Daniel H. Libraty

IPC分类号： A61K39/295 ,  A61K39/12 ,  A61K39/29 ,  A61K47/65 ,  A61P31/14 ,  A61P31/20

CPC分类号： A61K39/295 ,  A61K39/12 ,  A61K39/292 ,  A61K47/65 ,  A61P31/14 ,  A61P31/20

摘要： The present invention relates to the construction of and immunization with viral vaccines. In particular, bivalent vaccines that are capable of providing simultaneous virus infection protection for two or more different viruses. Furthermore, the bivalent vaccines contemplated herein are contemplated as being effective in a neonatal mammal. One such bivalent viral vaccine comprises two antigenic epitopes against the dengue viruses and at least one antigenic epitope against hepatitis B virus. Immunization cross-reactivity may also provide infection protection against other viruses as well.

公开(公告)号：US20240042015A1

公开(公告)日：2024-02-08

申请号：US17999378

申请日：2021-05-19

申请人： Orna Therapeutics, Inc.

发明人： Alexander Wesselhoeft ,  Thomas Barnes ,  Brian Goodman ,  Greg Motz ,  Amy Becker ,  Allen T. Horhota

IPC分类号： A61K39/295 ,  A61P37/04

CPC分类号： A61K39/295 ,  A61P37/04 ,  A61K2039/55555

摘要： Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

公开(公告)号：US11878054B2

公开(公告)日：2024-01-23

申请号：US16988659

申请日：2020-08-09

申请人： Inventprise, LLC

发明人： Subhash V. Kapre

IPC分类号： A61K39/29 ,  A61K39/295 ,  A61K47/42 ,  C07K14/025 ,  A61K39/12 ,  A61K9/00 ,  A61K9/19 ,  A61K47/10 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/10 ,  A61K47/42 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5258 ,  C12N2710/20034 ,  C12N2730/10123 ,  C12N2730/10142

摘要： The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

公开(公告)号：US20240009303A1

公开(公告)日：2024-01-11

申请号：US18250106

申请日：2021-10-28

申请人： Intervet Inc.

发明人： Sietske Kooijman ,  Ruud Philip Antoon Maria Segers ,  Maarten Hendrik Witvliet

IPC分类号： A61K39/295 ,  A61P31/12 ,  A61K39/02 ,  A61K39/12 ,  A61P31/04 ,  A61K39/385

CPC分类号： A61K39/295 ,  A61P31/12 ,  A61K39/0241 ,  A61K39/12 ,  A61P31/04 ,  A61K39/385 ,  A61K2039/552

摘要： The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protecting swine against an infection with porcine circo virus type 2, an infection with Mycoplasma hyopneumoniae and DON induced mycotoxicosis.

公开(公告)号：US11865174B2

公开(公告)日：2024-01-09

申请号：US17367296

申请日：2021-07-02

申请人： Hugh Mason ,  Andrew Diamos ,  Mary Pardhe ,  Brandon Favre

发明人： Hugh Mason ,  Andrew Diamos ,  Mary Pardhe ,  Brandon Favre

IPC分类号： A61K39/12 ,  A61K39/29 ,  A61K39/00 ,  A61K39/295 ,  A61P31/20 ,  C12N7/00 ,  A61K39/145

CPC分类号： A61K39/292 ,  A61K39/12 ,  A61K39/145 ,  A61P31/20 ,  C12N7/00 ,  A61K2039/505 ,  A61K2039/5258 ,  A61K2039/575 ,  A61K2039/6056 ,  A61K2039/70 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10171 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/24134 ,  C12N2770/24171

摘要： The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.

公开(公告)号：US20230330205A1

公开(公告)日：2023-10-19

申请号：US18163855

申请日：2023-02-02

申请人： RESILIENCE GOVERNMENT SERVICES, INC.

发明人： Ron COBB ,  Michael SPRINGER ,  Yawei NI

IPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/295 ,  A61K9/00 ,  A61K9/16 ,  A61K9/19

CPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/295 ,  A61K9/0095 ,  A61K9/1694 ,  A61K9/19 ,  A61K2039/5258 ,  A61K2039/55583 ,  C12N2770/16034 ,  A61K2039/541 ,  A61K2039/70 ,  C12N2770/16023 ,  C12N2770/16071

摘要： A dry powder Norovirus vaccine is provided, which comprises at least two Norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against Norovirus infections.

公开(公告)号：US20230201336A1

公开(公告)日：2023-06-29

申请号：US17996300

申请日：2021-03-09

申请人： ÖSTERREICHISCHE AGENTUR FÜR GESUNDHEIT UND ERNÄHRUNGSSICHERHEIT GMBH

发明人： Boris HARTMANN

IPC分类号： A61K39/295 ,  A61K39/145 ,  C07K14/005

CPC分类号： A61K39/295 ,  A61K39/145 ,  C07K14/005 ,  C12N2760/16123 ,  C12N2760/16134 ,  A61K2039/543

摘要： Disclosed are influenza



virus-like particles (VLPs), wherein the VLPs
include hemagglutinin (HA) protein and neuraminidase (NA) protein on the surface of the VLPs,
a nucleoprotein (NP) ribonucleoprotein complex, and
wherein the VLPs do not contain a ribonucleoprotein complex of at least one of PB1, PB2, and NS.